Published Jun 4, 2022
#694 Dexcom CEO chats from ADA 2022
Dexcom CEO Kevin Sayer shares groundbreaking insights at ADA 2022, discussing the expansion of CGM technology for Type 2 diabetes with the G6 sensor's performance and unveiling the enhanced usability and innovations of the new G7 sensor, aimed at transforming diabetes management.
Topics covered
Popular Clips
Questions from this episode
Episode Highlights
Related Episodes
#345 Dexcom CEO Returns
Answers 383 questions#116 Dexcom Update with CEO Kevin Sayer
Answers 383 questions
#954 Dexcom COO Jake Leach: G7, G6, Type 2 and your Questions
Answers 383 questions#234 Dexcom CEO Kevin Sayer Returns
Answers 383 questions#498 Dexcom G7 Talk With Dexcom CEO Kevin Sayer
Answers 383 questions#418 Dexcom G7 Update
Answers 383 questions#239 Dexcom Suggestion Box
Answers 383 questions#510 Dexcom G7 App Refresh with Dexcom CTO
Answers 383 questions
#782 Dexcom G7 User
Answers 383 questions#806 Dexcom G7 Approved By FDA (with Dexcom COO Jake Leach)
Answers 383 questions#158 Dexcom G6 Overview With Dexcom President Kevin Sayer
Answers 383 questions
#803 The Conversation Reveals All
Answers 383 questions
#309 Omnipod and Dexcom Updates
Answers 383 questions
#194 Dexcom Returns
Answers 383 questions
#890 Best of Juicebox: Dexcom Calibration Practices
Answers 383 questions